Skip to content
IeDEA International epidemiology Databases to Evaluate AIDS

IeDEA International epidemiology Databases to Evaluate AIDS

0Countries
0Sites
>0People living with and at risk for HIV
  • Home
    • Who We Are
  • Regions
    • Asia-Pacific
    • CCASAnet
    • Central Africa
    • East Africa
    • NA-ACCORD
    • Southern Africa
    • West Africa
  • Working Groups
    • Executive Committee
    • Adolescent and Young Adult Network of IeDEA (AYANI)
    • Cancer
    • Data Harmonization
    • Fogarty-IeDEA Mentorship Program (FIMP)
    • Hepatitis
    • Mental Health
    • Mother and Infant
    • Pediatrics
    • Sentinel Research Network (SRN)
    • Site Assessment
    • Strategic Data
    • Substance Use
    • Tuberculosis and Lung Health
  • Publications
    • Asia-Pacific
    • CCASAnet
    • Central Africa
    • East Africa
    • NA-ACCORD
    • Southern Africa
    • West Africa
    • Multi-regional
    • All publications
  • Resources
    • Fogarty-IeDEA Mentorship Program (FIMP)
    • Multiregional research SOPs, templates
    • Funding Acknowledgements
    • Consortium accomplishments
    • Meeting reports and presentations
      • CROI 2022 – IeDEA presentations
  • News
IeDEA International epidemiology Databases to Evaluate AIDS > Resources

Resources

– Multiregional research SOPs, templates

– Funding Acknowledgements

– Consortium accomplishments

– Meeting reports and presentations

– Fogarty-IeDEA Mentorship Program (FIMP)

 

News

  • Global Newsletter – JulyJuly 31, 2023
  • Fogarty-IeDEA Mentorship Program (FIMP)June 30, 2023
  • Global Newsletter – MayMay 31, 2023
  • Global Newsletter – MarchMarch 27, 2023
  • Research Highlights 2022February 7, 2023

Quick access

  • Who We Are
  • Regions
  • Working Groups
  • Publications
  • Resources

News

Global Newsletter – July

Read our latest global newsletter here.

Fogarty-IeDEA Mentorship Program (FIMP)

Applications due – Monday, October 23

Global Newsletter – May

Read our latest global newsletter here.

Global Newsletter – March

Read our latest Global Newsletter here.

Research Highlights 2022

Check out the IeDEA Global Research Highlights from 2022!

Tweets by @iedeaglobal

Tweets by iedeaglobal

Recent publications

2775998 369YB7BV items 1 3 default desc https://www.iedea.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22instance%22%3A%22zotpress-d3a4ceebb10c61f818704694fa8c08a1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TFADNKB5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fern%5Cu00e1ndez%20Villalobos%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EFern%26%23xE1%3Bndez%20Villalobos%2C%20Nathalie%20Ver%26%23xF3%3Bnica%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERuffieux%2C%20Yann%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EHaas%2C%20Andreas%20D.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EChinogurei%2C%20Chido%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ECornell%2C%20Morna%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Cervical%20precancer%20and%20cancer%20incidence%20among%20insured%20women%20with%20and%20without%20HIV%20in%20South%20Africa.%20%3Ci%3EInternational%20Journal%20of%20Cancer%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.34707%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.34707%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20precancer%20and%20cancer%20incidence%20among%20insured%20women%20with%20and%20without%20HIV%20in%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%20Ver%5Cu00f3nica%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%20Villalobos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chido%22%2C%22lastName%22%3A%22Chinogurei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katayoun%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naomi%22%2C%22lastName%22%3A%22Folb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Rohner%22%7D%5D%2C%22abstractNote%22%3A%22HIV%20infection%20increases%20the%20risk%20of%20developing%20cervical%20cancer%3B%20however%2C%20longitudinal%20studies%20in%20sub-Saharan%20Africa%20comparing%20cervical%20cancer%20rates%20between%20women%20living%20with%20HIV%20%28WLWH%29%20and%20women%20without%20HIV%20are%20scarce.%20To%20address%20this%20gap%2C%20we%20compared%20cervical%20precancer%20and%20cancer%20incidence%20rates%20between%20WLWH%20and%20women%20without%20HIV%20in%20South%20Africa%20using%20reimbursement%20claims%20data%20from%20a%20medical%20insurance%20scheme%20from%20January%202011%20to%20June%202020.%20We%20used%20Royston-Parmar%20flexible%20parametric%20survival%20models%20to%20estimate%20cervical%20precancer%20and%20cancer%20incidence%20rates%20as%20a%20continuous%20function%20of%20age%2C%20stratified%20by%20HIV%20status.%20Our%20study%20population%20consisted%20of%20518%5Cu2009048%20women%2C%20with%20exclusions%20based%20on%20the%20endpoint%20of%20interest.%20To%20analyse%20cervical%20cancer%20incidence%2C%20we%20included%20517%5Cu2009312%20women%2C%20of%20whom%20564%20developed%20cervical%20cancer.%20WLWH%20had%20an%20~3-fold%20higher%20risk%20of%20developing%20cervical%20precancer%20and%20cancer%20than%20women%20without%20HIV%20%28adjusted%20hazard%20ratio%20for%20cervical%20cancer%3A%202.99%3B%2095%25%20confidence%20interval%20%5BCI%5D%3A%202.40-3.73%29.%20For%20all%20endpoints%20of%20interest%2C%20the%20estimated%20incidence%20rates%20were%20higher%20in%20WLWH%20than%20women%20without%20HIV.%20Cervical%20cancer%20rates%20among%20WLWH%20increased%20at%20early%20ages%20and%20peaked%20at%2049%5Cu2009years%20%28122%5C%2F100%5Cu2009000%20person-years%3B%2095%25%20CI%3A%20100-147%29%2C%20whereas%2C%20in%20women%20without%20HIV%2C%20incidence%20rates%20peaked%20at%2056%5Cu2009years%20%2840%5C%2F100%5Cu2009000%20person-years%3B%2095%25%20CI%3A%2036-45%29.%20Cervical%20precancer%20rates%20peaked%20in%20women%20in%20their%2030s.%20Analyses%20of%20age-specific%20cervical%20cancer%20rates%20by%20HIV%20status%20are%20essential%20to%20inform%20the%20design%20of%20targeted%20cervical%20cancer%20prevention%20policies%20in%20Southern%20Africa%20and%20other%20regions%20with%20a%20double%20burden%20of%20HIV%20and%20cervical%20cancer.%22%2C%22date%22%3A%222023-09-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.34707%22%2C%22ISSN%22%3A%221097-0215%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22369YB7BV%22%5D%2C%22dateModified%22%3A%222023-09-07T03%3A48%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22WQSXYJBM%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22%5Cu00c1lvarez%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%26%23xC1%3Blvarez%2C%20Hortensia%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EMocroft%2C%20Amanda%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERyom%2C%20Lene%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ENeesgaard%2C%20Bastian%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EEdwards%2C%20Simon%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Plasma%20Human%20Immunodeficiency%20Virus%201%20RNA%20and%20CD4%2B%20T-Cell%20Counts%20Are%20Determinants%20of%20Virological%20Nonsuppression%20Outcomes%20With%20Initial%20Integrase%20Inhibitor-Based%20Regimens%3A%20A%20Prospective%20RESPOND%20Cohort%20Study.%20%3Ci%3EClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%3C%5C%2Fi%3E%2C%20%3Ci%3E77%3C%5C%2Fi%3E%20%284%29%2C%20S.%20593%26%23x2013%3B605.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad219%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad219%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasma%20Human%20Immunodeficiency%20Virus%201%20RNA%20and%20CD4%2B%20T-Cell%20Counts%20Are%20Determinants%20of%20Virological%20Nonsuppression%20Outcomes%20With%20Initial%20Integrase%20Inhibitor-Based%20Regimens%3A%20A%20Prospective%20RESPOND%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hortensia%22%2C%22lastName%22%3A%22%5Cu00c1lvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lene%22%2C%22lastName%22%3A%22Ryom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastian%22%2C%22lastName%22%3A%22Neesgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Svedhem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Huldrych%20F.%22%2C%22lastName%22%3A%22G%5Cu00fcnthard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Zangerle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colette%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22Castagna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22d%27Arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdinand%22%2C%22lastName%22%3A%22Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22Stecher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%22%2C%22lastName%22%3A%22Lehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Fontas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Christian%22%2C%22lastName%22%3A%22Wasmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%22%2C%22lastName%22%3A%22S%5Cu00f6nnerborg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22De%20Wit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikoloz%22%2C%22lastName%22%3A%22Chkhartishvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Stephan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathy%22%2C%22lastName%22%3A%22Petoumenos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Jaschinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vani%22%2C%22lastName%22%3A%22Vannappagari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joel%22%2C%22lastName%22%3A%22Gallant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lital%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Volny%20Anne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Greenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Mart%5Cu00edn-Iguacel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Poveda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%20M.%22%2C%22lastName%22%3A%22Llibre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RESPOND%20%28International%20Cohort%20Consortium%20of%20Infectious%20Diseases%29%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20There%20are%20conflicting%20data%20regarding%20baseline%20determinants%20of%20virological%20nonsuppression%20outcomes%20in%20persons%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20starting%20antiretroviral%20treatment%20%28ART%29.%20We%20evaluated%20the%20impact%20of%20different%20baseline%20variables%20in%20the%20RESPOND%20cohort.%5CnMETHODS%3A%20We%20included%20treatment-naive%20participants%20aged%20%5Cu226518%20who%20initiated%203-drug%20ART%2C%20in%202014-2020.%20We%20assessed%20the%20odds%20of%20virological%20suppression%20%28VS%29%20at%20weeks%2048%20and%2096%20using%20logistic%20regression.%20Viral%20blips%2C%20low-level%20viremia%20%28LLV%29%2C%20residual%20viremia%20%28RV%29%2C%20and%20virological%20failure%20%28VF%29%20rates%20were%20assessed%20using%20Cox%20regression.%5CnRESULTS%3A%20Of%204310%20eligible%20participants%2C%2072%25%20started%20integrase%20strand%20transfer%20inhibitor%20%28INSTI%29-based%20regimens.%20At%2048%20and%2096%20weeks%2C%2091.0%25%20and%2093.3%25%20achieved%20VS%2C%20respectively.%20At%2048%20weeks%2C%20Kaplan-Meier%20estimates%20of%20rates%20were%209.6%25%20for%20viral%20blips%2C%202.1%25%20for%20LLV%2C%2022.2%25%20for%20RV%2C%20and%202.1%25%20for%20VF.%20Baseline%20HIV-1%20RNA%20levels%20%3E100%20000%20copies%5C%2FmL%20and%20CD4%2B%20T-cell%20counts%20%5Cu2264200%5C%2F%5Cu00b5L%20were%20negatively%20associated%20with%20VS%20at%20weeks%2048%20%28adjusted%20odds%20ratio%2C%200.51%20%5B95%25%20confidence%20interval%2C%20.39-.68%5D%20and%20.40%20%5B.27-.58%5D%2C%20respectively%29%20and%2096%20and%20with%20significantly%20higher%20rates%20of%20blips%2C%20LLV%2C%20and%20RV.%20CD4%2B%20T-cell%20counts%20%5Cu2264200%5C%2F%5Cu00b5L%20were%20associated%20with%20higher%20risk%20of%20VF%20%28adjusted%20hazard%20ratio%2C%203.12%20%5B95%25%20confidence%20interval%2C%202.02-4.83%5D%29.%20Results%20were%20consistent%20in%20those%20starting%20INSTIs%20versus%20other%20regimens%20and%20those%20starting%20dolutegravir%20versus%20other%20INSTIs.%5CnCONCLUSIONS%3A%20Initial%20high%20HIV-1%20RNA%20and%20low%20CD4%2B%20T-cell%20counts%20are%20associated%20with%20lower%20rates%20of%20VS%20at%2048%20and%2096%20weeks%20and%20higher%20rates%20of%20viral%20blips%2C%20LLV%2C%20and%20RV.%20Low%20baseline%20CD4%2B%20T-cell%20counts%20are%20associated%20with%20higher%20VF%20rates.%20These%20associations%20remain%20with%20INSTI-based%20and%20specifically%20with%20dolutegravir-based%20regimens.%20These%20findings%20suggest%20that%20the%20impact%20of%20these%20baseline%20determinants%20is%20independent%20of%20the%20ART%20regimen%20initiated.%22%2C%22date%22%3A%222023-08-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad219%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22369YB7BV%22%5D%2C%22dateModified%22%3A%222023-09-07T03%3A48%3A19Z%22%7D%7D%2C%7B%22key%22%3A%223HM3BUCD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3E%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EParcesepe%2C%20Angela%20M.%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EStockton%2C%20Melissa%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3ERemch%2C%20Molly%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EWester%2C%20C.%20William%3C%5C%2Fspan%3E%3B%20%3Cspan%20style%3D%5C%22text-decoration%3Anone%3B%5C%22%3EBernard%2C%20Charlotte%3C%5C%2Fspan%3E%20et%20al.%3C%5C%2Fspan%3E%20%282023%29.%20Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020.%20%3Ci%3EJournal%20of%20the%20International%20AIDS%20Society%3C%5C%2Fi%3E%2C%20%3Ci%3E26%3C%5C%2Fi%3E%20%288%29%2C%20S.%20e26147.%20%3Ca%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Molly%22%2C%22lastName%22%3A%22Remch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junko%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Common%20mental%20disorders%20%28CMDs%29%20are%20highly%20prevalent%20among%20people%20with%20HIV.%20Integrating%20mental%20healthcare%20into%20HIV%20care%20may%20improve%20mental%20health%20and%20HIV%20treatment%20outcomes.%20We%20describe%20the%20reported%20availability%20of%20screening%20and%20treatment%20for%20depression%2C%20anxiety%20and%20post-traumatic%20stress%20disorder%20%28PTSD%29%20at%20global%20HIV%20treatment%20centres%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%20in%202020%20and%20changes%20in%20availability%20at%20sites%20in%20low-%20or%20middle-income%20countries%20%28LMICs%29%20between%202016%5C%2F2017%20and%202020.%5CnMETHODS%3A%20In%202020%2C%20238%20sites%20contributing%20individual-level%20data%20to%20the%20IeDEA%20Consortium%20and%20in%202016%5C%2F2017%20a%20stratified%20random%20sample%20of%20IeDEA%20sites%20in%20LMICs%20were%20eligible%20to%20participate%20in%20site%20surveys%20on%20the%20availability%20of%20screening%20and%20treatment%20for%20CMDs.%20We%20assessed%20trends%20over%20time%20for%2068%20sites%20across%2027%20LMICs%20that%20participated%20in%20both%20surveys.%5CnRESULTS%3A%20Among%20the%20238%20sites%20eligible%20to%20participate%20in%20the%202020%20site%20survey%2C%20227%20%2895%25%29%20participated%2C%20and%20mental%20health%20screening%20and%20treatment%20data%20were%20available%20for%20223%20%2898%25%29%20sites%20across%2041%20countries.%20A%20total%20of%2095%20sites%20across%2029%20LMICs%20completed%20the%202016%5C%2F2017%20survey.%20In%202020%2C%2068%25%20of%20sites%20were%20in%20urban%20settings%2C%20and%2077%25%20were%20in%20LMICs.%20Overall%2C%2050%25%2C%2014%25%20and%2012%25%20of%20sites%20reported%20screening%20with%20a%20validated%20instrument%20for%20depression%2C%20anxiety%20and%20PTSD%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20counselling%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2046%25%2C%2013%25%20and%2011%25%20of%20sites%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20medication%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2036%25%2C%2011%25%20and%208%25%20of%20sites%2C%20respectively.%20Among%20sites%20that%20participated%20in%20both%20surveys%2C%20screening%20for%20depression%20was%20more%20commonly%20available%20in%202020%20than%202016%5C%2F2017%20%2875%25%20vs.%2059%25%2C%20respectively%2C%20p%20%3D%200.048%29.%5CnCONCLUSIONS%3A%20Reported%20availability%20of%20screening%20for%20depression%20increased%20among%20this%20group%20of%20IeDEA%20sites%20in%20LMICs%20between%202016%5C%2F2017%20and%202020.%20However%2C%20substantial%20gaps%20persist%20in%20the%20availability%20of%20mental%20healthcare%20at%20HIV%20treatment%20sites%20across%20global%20settings%2C%20particularly%20in%20resource-constrained%20settings.%20Implementation%20of%20sustainable%20strategies%20to%20integrate%20mental%20health%20services%20into%20HIV%20care%20is%20needed.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26147%22%2C%22ISSN%22%3A%221758-2652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22369YB7BV%22%5D%2C%22dateModified%22%3A%222023-09-07T03%3A48%3A00Z%22%7D%7D%5D%7D
Fernández Villalobos, Nathalie Verónica; Ruffieux, Yann; Haas, Andreas D.; Chinogurei, Chido; Cornell, Morna et al. (2023). Cervical precancer and cancer incidence among insured women with and without HIV in South Africa. International Journal of Cancer. http://doi.org/10.1002/ijc.34707.
Álvarez, Hortensia; Mocroft, Amanda; Ryom, Lene; Neesgaard, Bastian; Edwards, Simon et al. (2023). Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 77 (4), S. 593–605. http://doi.org/10.1093/cid/ciad219.
Parcesepe, Angela M.; Stockton, Melissa; Remch, Molly; Wester, C. William; Bernard, Charlotte et al. (2023). Availability of screening and treatment for common mental disorders in HIV clinic settings: data from the global International epidemiology Databases to Evaluate AIDS (IeDEA) Consortium, 2016-2017 and 2020. Journal of the International AIDS Society, 26 (8), S. e26147. http://doi.org/10.1002/jia2.26147.
  • Home
    • Who We Are
  • Regions
    • Asia-Pacific
    • CCASAnet
    • Central Africa
    • East Africa
    • NA-ACCORD
    • Southern Africa
    • West Africa
  • Working Groups
    • Executive Committee
    • Adolescent and Young Adult Network of IeDEA (AYANI)
    • Cancer
    • Data Harmonization
    • Fogarty-IeDEA Mentorship Program (FIMP)
    • Hepatitis
    • Mental Health
    • Mother and Infant
    • Pediatrics
    • Sentinel Research Network (SRN)
    • Site Assessment
    • Strategic Data
    • Substance Use
    • Tuberculosis and Lung Health
  • Publications
    • Asia-Pacific
    • CCASAnet
    • Central Africa
    • East Africa
    • NA-ACCORD
    • Southern Africa
    • West Africa
    • Multi-regional
    • All publications
  • Resources
    • Fogarty-IeDEA Mentorship Program (FIMP)
    • Multiregional research SOPs, templates
    • Funding Acknowledgements
    • Consortium accomplishments
    • Meeting reports and presentations
      • CROI 2022 – IeDEA presentations
  • News
IeDEA International epidemiology Databases to Evaluate AIDS Proudly powered by WordPress

This site was developed by the Institute of Social and Preventive Medicine (ISPM) at the University of Bern for NIAID, under cooperative agreement number U01AI069924. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the NIAID or the U.S. Government.
Sponsored by: NIAID, NCI, NICHD, NIMH, NHLBI, NIDDK, NLM, NIAAA, FIC and NIDA.